$11.25
-0.10 (-0.88%)
Open$11.34
Previous Close$11.35
Day High$11.37
Day Low$10.80
52W High$33.20
52W Low$10.47
Volume—
Avg Volume565.9K
Market Cap481.93M
P/E Ratio—
EPS$-3.87
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+573.8% upside
Current
$11.25
$11.25
Target
$75.80
$75.80
$52.19
$75.80 avg
$91.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.51M | 78.02M | 75.69M |
| Net Income | -98,085,830 | -16,723,517 | -20,379,208 |
| Profit Margin | -529.8% | -21.4% | -26.9% |
| EBITDA | -113,486,038 | -28,105,243 | -27,281,553 |
| Free Cash Flow | — | -11,355,754 | -12,035,038 |
| Rev Growth | — | -7.7% | +21.3% |
| Debt/Equity | 0.00 | 0.34 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |